March 19, 2026 a 11:43 am
INCY: Fundamental Ratio Analysis - Incyte Corporation
Incyte Corporation, with its robust portfolio of proprietary therapeutics, holds a significant position in the biopharmaceutical industry. Priced competitively, INCY stock reflects a promise of steady growth backed by strong clinical developments and strategic collaborations. However, market volatility and drug approval challenges remain as potential risks.
Fundamental Rating
The company maintains an impressive overall fundamental score. The scores for key financial metrics indicate a strong positioning in profitability and growth potential. Below is a detailed breakdown:
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 4 | |
| Price to Earnings | 2 | |
| Price to Book | 2 |
Historical Rating
Comparison of current fundamental scores with previous data demonstrates consistent financial strength:
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-03-18 | 4 | 5 | 5 | 5 | 4 | 2 | 2 |
| Previously | 0 | 5 | 5 | 5 | 4 | 2 | 2 |
Analyst Price Targets
The analyst price targets indicate potential upside for INCY with a consensus close to the median value:
| High | Low | Median | Consensus |
|---|---|---|---|
| $135 | $84 | $108.5 | $108.9 |
Chart depicting stock price trends and analyst forecasts.
Analyst Sentiment
Analyst recommendations show a strong inclination towards buying, reflecting confidence in the company's future performance:
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 24 | |
| Hold | 18 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Incyte Corporation exhibits a strong market positioning with consistently high scores in key financial metrics, coupled with a promising drug development pipeline. Analyst sentiment is generally positive, with a notable preference for buying the stock. However, potential regulatory challenges and the inherent volatility of the biotech sector represent risk factors that must be monitored. Overall, INCY stands as a solid investment opportunity with substantial growth potential.